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PURPOSE. Growing evidence indicates neuroprotection as a therapeutic target in diabetic
retinopathy (DR). We tested the hypothesis that VEGF is released and acts as a survival factor
in the retina in early DR.
METHODS. Ex vivo mouse retinal explants were exposed to stressors similar to those
characterizing DR, that is, high glucose (HG), oxidative stress (OS), or advanced glycation
end-products (AGE). Neuroprotection was provided using octreotide (OCT), a somatostatin
analog, and pituitary adenylate cyclase activating peptide (PACAP), two well-documented
neuroprotectants. Data were obtained with real-time RT-PCR, Western blot, ELISA, and
immunohistochemistry.
RESULTS. Apoptosis was induced in the retinal explants by HG, OS, or AGE treatments. At
the same time, explants also showed increased VEGF expression and release. The data
revealed that VEGF is released shortly after exposure of the explants to stressors and
before the level of cell death reaches its maximum. Retinal cell apoptosis was inhibited by
OCT and PACAP. At the same time, OCT and PACAP also reduced VEGF expression and
release. Vascular endothelial growth factor turned out to be a protective factor for the
stressed retinal explants, because inhibiting VEGF with a VEGF trap further increased cell
death.
CONCLUSIONS. These data show that protecting retinal neurons from diabetic stress also
reduces VEGF expression and release, while inhibiting VEGF leads to exacerbation of
apoptosis. These observations suggest that the retina in early DR releases VEGF as a
prosurvival factor. Neuroprotective agents may decrease the need of VEGF production by the
retina, therefore limiting the risk, in the long term, of pathologic angiogenesis.
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Diabetic retinopathy (DR) is the most common complica-tion of type 1 and type 2 diabetes. Most studies in DR
focus on blood vessel pathology, and pharmacologic treat-
ments mainly target VEGF. However, numerous reports have
established that functional alterations and degeneration of
retinal neurons precede and possibly activate microangio-
pathic processes and disruption of the blood–retinal barri-
er,1–6 supporting the view that DR may be considered a
neurodegenerative eye disease.3
We have recently reported that retinal neurons subjected
to acute ischemic stress express and release VEGF.7,8 In this
context, the significance of VEGF release is unlikely to be
related to its proangiogenic effects. Rather, VEGF expression
and release are probably related to a protective strategy of the
retina, because VEGF may exert important neuroprotective
actions in the presence of a variety of insults, as observed in
neuronal cell lines,9–11 in the spinal cord,12 in the brain,13,14
and in the retina.14–20 Our hypothesis is that, in early DR,
VEGF is expressed and released to protect retinal neurons. In
this phase, VEGF would not act as a proangiogenic but as a
prosurvival factor. If the stress remains for a long time, the
persistent high levels of VEGF may lead to negative
consequences, such as the formation of new, aberrant retinal
vessels.
If neurodegeneration plays a primary role in initiating the
neovascular response typical of DR, then a neuroprotective
strategy may prove useful in early stages of DR to prevent the
development of both functional and vascular pathologies. Many
different substances have been tested for their neuroprotective
and/or antiangiogenic properties. A consistent body of exper-
imental evidence indicates neuropeptides or neuropeptide
analogs as effective neuroprotective agents in models of retinal
disease. In particular, the somatostatin analog octreotide (OCT)
and the peptide pituitary adenylate cyclase activating peptide
(PACAP) seem to be the most promising peptidergic substances
in this context.7,8,21–23
In this work, we used organotypic mouse retinal explants
cultured in the presence of stressors that characterize the
retinal environment in DR, namely high glucose (HG), oxidative
stress (OS), or advanced glycation end-products (AGE) to: (1)
verify that neuronal damage caused by diabetic stress is
accompanied by expression and release of VEGF, (2) test the
hypothesis that neuroprotection may limit the release of VEGF,
(3) ascertain whether VEGF may act as a neuroprotective factor
in the diabetic retina.
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METHODS
Animals
The procedures were approved by the Ethics Committee in
Animal Experiments of the University of Pisa (Pisa, Italy) and
were in compliance with the ARVO Statement for the Use of
Animals in Ophthalmic and Vision Research, the Italian
guidelines for animal care (DL 116/92), and the EU Directive
(2010/63/EU). All efforts were made to reduce both animal
suffering and the number of animals used. C57BL/6J mice
(Charles River Laboratories, Inc., Wilmington, MA, USA) were
used in these studies. They were kept in a regulated environment
(23 6 18C, 50 6 5% humidity) with a 12-hour light/dark cycle
(lights on at 8 AM) with food and water ad libitum.
Ex Vivo Retinal Explants
Retinas from 4- to 5-week-old mice were dissected in Modified
Eagle Medium (MEM; Sigma-Aldrich Corp., St. Louis, MO, USA)
and cut into four fragments. Fragments were transferred onto
Millicell-CM culture inserts (Merck Millipore, Darmstadt,
Germany) with ganglion cells up. Inserts were placed in six-
well tissue culture plates containing 1 mL of serum-free
culture medium composed of 50% MEM/HEPES (Sigma-
Aldrich Corp.) containing 6 mM D-glucose, 25% Hank’s buffer
salt solution (Sigma-Aldrich Corp.), 25% PBS, 25 U/mL
penicillin, 25 mg/mL streptomycin, 1 lg/mL amphotericin
B, and 200 lM L-glutamine. The first day in culture was
designated as incubation day 0. The explants were incubated
up to day 10 at 378C under a humidified 95%/5% (vol/vol)
mixture of air and CO2. The medium was changed every other
day. High glucose treatments were performed adding D-
glucose to the culture medium to reach a concentration of 45
or 75 mM, according to previous studies. Indeed, although a
HG treatment resembling a diabetes-induced glucose increase
is generally set at 25 to 35 mM glucose, in many studies HG
treatments have been performed using a wide variety of
glucose concentrations. In particular, in rodent retinal
explants maintained in serum-free medium, HG treatments
were performed using 45 to 57 mM glucose,24–27 while 75
mM glucose has been used for hyperglycemic treatment of
primary cultures of hippocampal neurons.28 In our prelimi-
nary experiments, treatments with 75 mM glucose were
necessary to induce significant increases of apoptotic markers
in retinal explants maintained in serum-free medium up to 10
days. Oxidative stress treatments were performed adding
H2O2 to reach a concentration of 10 lM or 100 lM,29 while
AGE treatments were performed adding 10 lg/mL or 100 lg/
mL AGE-BSA (BioVision, Milpitas, CA, USA) to culture
medium.30 Control experiments were performed incubating
the explants in the culture medium with the addition of 69
mM mannitol (HG control) or of 100 lg/mL BSA (AGE
control). An analysis of apoptotic cell death using caspase-3
immunolabeling showed lack of significant differences
between untreated and mannitol- or BSA-treated explants
during a 10-day incubation period (Supplementary Fig. S1).
These observations were in agreement with previous studies
of rat retinal explants.24–26 On the basis of these findings, only
one type of control (i.e., untreated explants) was used in the
experiments with HG, OS, and AGE treatments.
Pharmacological Treatments
The soatostatin analogue OCT (a long-lasting somatostatin
subtype receptor 2 agonist; Sigma-Aldrich Corp.), was used at 1
lM, while PACAP-38 (Sigma-Aldrich Corp.) was used at 0.1
lM.8 A VEGF trap (R&D Systems, Minneapolis, MN, USA),
which is a recombinant soluble Flt-1/Fc chimera with
homodimer structure binding all forms of VEGF with high
affinity, was applied at 1 lM.7 Control experiments were
performed using a VEGF trap that was preincubated overnight
at 48C in culture medium with double molar concentration of
recombinant VEGF.
Immunofluorescence
Retinal fragments were fixed in 4% paraformaldehyde in 0.1M
phosphate buffer for 1 hour. They were stored overnight in
25% sucrose in 0.1 M phosphate buffer and subsequently
embedded in cryo-gel and frozen using liquid nitrogen.
Immunofluorescence was performed using a rabbit antibody
directed to active caspase-3 (1:500; Sigma-Aldrich Corp.) and
appropriate secondary antibodies conjugated with Alexa Fluor
546 (Molecular Probes, Eugene, OR, USA). Retinal sections
were counterstained with DAPI. Digital images were acquired
at320 or340 magnification. To perform quantitative analysis,
at least five representative images were selected for each
retinal fragment and four fragments, each originating from a
different retina, for experimental condition were analyzed.
Each image was converted to grayscale and normalized to
background using an image editing software (Adobe Photo-
shop CS3; Adobe Systems, Mountain View, CA, USA). Mean
gray levels were then measured in the area encompassing the
ganglion cell layer (GCL), the inner plexiform layer (IPL), and
the inner nuclear layer (INL).
Western Blot
Four retinal fragments per condition, each originating from a
different retina, were pooled and sonicated in 70 lL of 10 mM
Tris/HCl, pH 7.6, containing 5 mM EDTA, 3 mM EGTA, 250 mM
sucrose, and protease and phosphatase inhibitor cocktails.
Homogenates were centrifuged at 22,000 g for 15 minutes at
48C. The supernatants, containing cytosolic proteins, were
used to detect cytochrome c. The supernatants were also used
to measure VEGF content with ELISA (see below). Protein
concentration was determined using a fluorometer (Qubit;
Invitrogen, Carlsbad, CA, USA). Aliquots of each sample (30 lg
protein) were subjected to SDS-PAGE. The gels were trans-
blotted onto polyvinylidene difluoride (PVDF) membranes
(Bio-Rad Laboratories, Inc., Hercules, CA, USA). Membranes
were blocked in 3% skim milk for 1 hour and then incubated
overnight at 48C with mouse monoclonal antibodies directed
to cytochrome c (BD Biosciences, San Diego, CA, USA) diluted
1:500. The membranes were reblotted with a mouse mono-
clonal antibody directed to b-actin (1:2500; Sigma-Aldrich
Corp.) used as the loading control. Finally, PVDF membranes
were incubated for 1 hour with anti-mouse (1:12,500)
horseradish peroxidase-labeled secondary antibodies (Santa
Cruz Biotechnologies, Dallas, TX, USA) and developed with the
enhanced chemiluminescence reagent. Images were acquired
using Chemidoc XRSþ (Bio-Rad). Band optical density was
evaluated with Image Lab 3.0 software (Bio-Rad). The data
were normalized to b-actin. All experiments were run in
duplicate. After statistics, data were averaged and plotted in the
same graph.
Isolation of RNA and cDNA Preparation
Four retinal fragments per condition were pooled and total
RNA was extracted using a RNA isolation kit (RNeasy Mini Kit;
Qiagen, Hilden, Germany), purified, resuspended in RNase-free
water and quantified using a fluorometer. First-strand cDNA
was generated from 1 lg of total RNA using QuantiTect Reverse
Transcription Kit (Qiagen).
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Quantitative Real-Time RT-PCR
Quantitative real-time RT-PCR (qPCR) was performed as
previously reported.31 To evaluate gene expression, qPCR
experiments were performed using the SYBR Green PCR Kit
(Qiagen). Forward and reverse primers were chosen to
hybridize to unique regions of the appropriate gene sequence:
Caspase-3 forward 5 0-GCACTGGAATGTCATCTCGCTCTG-3 0;
Caspase-3 reverse 50-GCCCATGAATGTCTCTCTGAGGTTG-30;
VEGF forward 50-GCACATAGGAGAGATGAGCTTCC-3 0; VEGF
reverse 50-CTCCGCTCTGAACAAGGCT-30; Rpl13a forward 50-
CACTCTGGAGGAGAAACGGAAGG-3 0; Rpl13a reverse 5 0-
GCAGGCATGAGGCAAACAGTC-3 0. Amplification efficiency
was close to 100% for each primer pair. Each target gene was
run concurrently with Rpl13a, a constitutively expressed gene
encoding a ribosomal protein that is a component of the 60S
subunit. To confirm that this transcript could be used as a
suitable housekeeping/reference gene, it was validated in
mouse retinal fragments both untreated and treated with the
different stressors (Supplementary Table S1). Samples were
compared using the relative threshold cycle (Ct Method).32
The increase or decrease (x-fold) was determined relative to a
control after normalizing to Rpl13a. Three pools of fragments
per condition, each made of four retinal fragments originating
from different retinas, were analyzed and all reactions were run
in triplicate. After statistical analysis, the data from the different
experiments were plotted and averaged in the same graph.
Enzyme-Linked Immunosorbent Assay (ELISA)
Vascular endothelial growth factor levels were measured (n¼3
per condition) in culture mediums to evaluate VEGF release or
in supernatants containing cytosolic proteins to evaluate VEGF
content in the tissue, using a kit (R&D Systems). The ELISA
plates were evaluated spectrophotometrically (Microplate
Reader 680 XR; Bio-Rad). All experiments were run in
duplicate. After statistical analysis, data from the different
experiments were plotted and averaged in the same graph.
Statistics
Statistical significance was evaluated using ANOVA followed by
Newman-Keuls Multiple Comparison post-test. The results are
expressed as mean 6 SEM. Differences with P less than 0.05
were considered significant.
RESULTS
Analysis of Cell Death
For each experimental model, we used a low and a high dose
of stressor and we determined a short and a long incubation
time, as reported in the Table. The short incubation time was
the day when caspase-3 immunolabeled cells were first
detected using the high dose of stressor, while the long
incubation time was the day when the maximum amount of
caspase-3 immunolabeled cells was detected using the high
dose of stressor. During the 10 days in culture, retinal explants
maintained a normal morphology, with clear distinction of the
retinal layers and no apparent changes in layer thickness.
Figure 1 shows the time-course of apoptosis in untreated
control explants and in explants treated with high doses of
stressors. In untreated explants (Fig. 1A), a few caspase-3
immunolabeled cells were detected in the INL and GCL from
day 3. In HG- (Fig. 1B), OS- (Fig. 1C), and AGE- (Fig. 1D) treated
explants, caspase-3 immunolabeled cells were first detected
between day 1 and 2, while their highest numbers were
observed between day 5 and 10. In particular, an analysis of
immunofluorescence levels showed that apoptotic levels did
not change significantly in untreated explants from day 3 to 10
(Fig. 1E), while maximum apoptotic levels were reached at day
10 in HG-treated explants (Fig. 1F), at day 5 in OS-treated
explants (Fig. 1G), and at day 7 in AGE-treated explants (Fig.
1H). The apoptotic effects of each stressor were dose-
dependent, as shown by Western blotting for cytochrome c,
an apoptosis marker, in the presence of the low or the high
dose of each stressor at the long incubation times (Fig. 2).
Protective Effects of OCT and PACAP
Incubation with OCT or PACAP protected the retinal explants
from the stress induced by HG, OS, or AGE treatments with the
high doses and for the long incubation periods, as assessed
with caspase-3 immunofluorescence. Figure 3 shows repre-
sentative images of HG-treated explants. Similar results were
obtained with OS and with AGE-treated explants. Untreated
explants (Fig. 3A), showed an amount of caspase-3 immunola-
beled cells that was similar to that in the presence of OCT (Fig.
3B) or PACAP (Fig. 3C) alone. Caspase-3 immunoreactive cells
were dramatically increased by HG treatment (Fig. 3D), but
they were decreased back to untreated levels in HG-treated
explants incubated in the presence of OCT (Fig. 3E) or PACAP
(Fig. 3F). These results show that OCT and PACAP exert potent
protective effects in stressed retinal explants. In addition, the
incubation with OCT or PACAP alone did not affect caspase-3
immunolabeling and did not induce changes in the retinal
layers or in retinal cells, as assessed with DAPI counterstain.
The analysis of mean gray levels in immunofluorescence
images (Fig. 3G) confirmed these observations.
Cell Death and VEGF Expression
We tested whether VEGF expression was correlated with the
extent of neuronal damage and whether it may be reduced by
protecting the neurons from the stress due to HG, OS, or AGE
treatments with the high doses and for the long incubation
periods. As shown in Figure 4A, the levels of caspase-3 mRNA,
a measure of cell death, were significantly increased by HG,
while they recovered to control values in explants treated with
OCT or PACAP. In parallel, the levels of VEGF mRNA were
almost doubled in HG-treated explants, while they were similar
to those in control explants after treatment with OCT or
PACAP (Fig. 4B). Similarly, OS treatment induced a 3-fold
increase of caspase-3 mRNA expression, while OCT or PACAP
inhibited this increase (Fig. 4C). Vascular endothelial growth
factor mRNA levels were also increased by OS and they were
reduced to control levels by OCT or below control levels by
PACAP (Fig. 4D). In AGE-treated explants, caspase-3 mRNA
TABLE. Stressor Doses and Incubation Times for Each Experimental Model
Model Stressor Low Dose High Dose Short Incubation Long Incubation
HG D-glucose 45 mM 75 mM Day 2 Day 10
OS H2O2 10 lM 100 lM Day 1 Day 5
AGE AGE 10 lg/mL 100 lg/mL Day 2 Day 7
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expression was more than doubled with respect to untreated
controls, while treatments with OCT or PACAP reduced
caspase-3 mRNA expression to control levels (Fig. 4E). Vascular
endothelial growth factor mRNA in AGE-treated explants was
also markedly increased, but OCT or PACAP treatments
completely prevented this effect (Fig. 4F).
VEGF Release
We evaluated VEGF release from stressed retinal explants and
tested whether neuroprotection could limit this release.
Vascular endothelial growth factor levels in the medium of
untreated control explants did not change significantly
between day 2 and 10, and they were approximately 0.6 pg/
mL. Vascular endothelial growth factor was also measured in
the retinal explants and its value was approximately 25 pg/mg
of protein. Vascular endothelial growth factor levels were
measured in HG-, OS-, and AGE-treated explants with similar
results. Representative examples are shown in Figure 5, which
summarizes an analysis of VEGF levels in AGE-treated explants
and in their incubation media at the short and the long
incubation times in the presence of the low or the high dose of
stressor. Vascular endothelial growth factor levels were
significantly decreased in AGE-treated explants compared with
untreated controls, independent of the incubation time and of
the dose of stressor (Fig. 5A). In contrast, VEGF levels in the
incubation medium increased indicating both time- and dose-
dependency (Fig. 5B). The values of the ratio between VEGF
levels in the explant tissue and those in its incubation medium
(Fig. 5C) were significantly reduced by AGE treatment at all
FIGURE 1. Representative immunofluorescence images showing active caspase-3 immunolabeled cells at different incubation times (days) in
untreated explants (A) and in explants incubated with the high dose of HG (B), OS (C), or AGE (D) treatments, together with the quantitative
analyses of immunofluorescence levels ([E] untreated; [F] HG-treated explants; [G] OS-treated explants; [H] AGE-treated explants). Retinal layers are
visualized with DAPI counterstain. Scale bar: 50 lm. *P < 0.05, **P < 0.01, ***P < 0.001 relative to untreated at day 3 (dashed lines); §P < 0.05, §§§P
< 0.001 relative to previous incubation day. Glu, D-glucose; ONL, outer nuclear layer; OPL, outer plexiform layer.
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incubation times and doses, indicating that a considerable part
of the VEGF contained in the tissue was released upon
exposure to AGE. The graph with the sum of VEGF in the
explant tissue plus VEGF in the medium (Fig. 5D) shows a
tendency of these values to increase with the incubation time
and with the stressor dose, reaching statistical significance at
day 7 with the dose of 100 lg/mL and indicating that the
treatment determined an overall increase of the VEGF
produced by the explants.
The effects of the treatment with OCT or with PACAP on
the levels of VEGF release were evaluated at the short
incubation time of each experimental model to ascertain
whether VEGF release is initiated before substantial cell death
is detected and whether neuroprotection may have an effect
on VEGF release at this early phase. As shown in Figure 6, in all
three experimental models an important increase of VEGF
release was observed in the stressed explants, but it was
completely abolished by OCT or PACAP. In particular, in HG-
treated explants, both OCT and PACAP treatments significantly
reduced VEGF release below control levels.
Neuroprotective Effects of VEGF
These experiments were conducted on HG explants treated
with 45 mM glucose and with a VEGF trap, analyzed at day 10.
The low dose of stressor was used to avoid massive cell death
that could mask the expected effects of the VEGF trap. Active
caspase-3 immunofluorescence revealed only a few labeled
cells in untreated control explants (Fig. 7A) or in explants
treated with the VEGF trap alone (Fig. 7B). A slight increase in
active caspase-3 immunolabeling was observed in the presence
of 45 mM glucose (Fig. 7C), but the immunolabeling
dramatically increased in the presence of 45 mM glucose
together with the VEGF trap (Fig. 7D). This increase was not
seen when using a VEGF trap that had been preincubated with
recombinant VEGF (Fig. 7E). The analysis of mean gray levels in
immunofluorescence images showed that the increase of
active caspase-3 immunolabeling caused by 45 mM glucose
was very limited and not statistically significant, but the
addition of the VEGF trap determined a 10-fold increase of the
immunolabeling relative to untreated controls, while a VEGF
trap preincubated with VEGF had no effects (Fig. 7F). These
FIGURE 2. Western blotting for cytochrome c as a measure of apoptotic levels in retinal explants treated with the low and the high dose of each
stressor in the HG (A), OS (B), and AGE (C) models at their long incubation times. *P < 0.05, **P < 0.01 relative to untreated; §§P < 0.01 relative to
low dose.
FIGURE 3. Representative immunofluorescence images showing active
caspase-3 immunolabeled cells at day 10 in untreated explants (A), in
explants incubated with OCT (B), or PACAP (C), and in explants
treated with the high dose of HG alone (D) or in combination with
OCT (E) or PACAP (F). Retinal layers are visualized with DAPI
counterstain. (G) Quantitative analysis of immunofluorescence levels.
Scale bar: 50 lm. ***P < 0.001 relative to untreated (dashed line).
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observations were confirmed with qPCR measures of caspase-3
mRNA expression. Indeed, as shown in Figure 7G, the pattern
of caspase-3 expression in the different experimental condi-
tions was the same as that observed with the gray level analysis
of immunolabeled sections. The levels of caspase transcripts in
HG explants treated with VEGF trap was 4- to 5-fold that in
untreated controls or in VEGF trap-only–treated explants.
DISCUSSION
In early DR, high levels of glucose result in retinal damage
because they activate a series of negative intracellular responses,
including (although not limited to) OS and AGE formation.
Oxidative stress may be secondary to disrupted retinal glutamate
homeostasis and excitotoxicity or to a variety of intracellular
pathways activated by HG and may cause inflammation,
reduction of naturally expressed neuroprotectants and cell
death, while AGE formation is induced by HG and has been
observed to result in neuronal death in rodent retinal explants.33
Oxidative stress and AGE production are likely to be interrelated,
because AGE can induce OS, while AGE synthesis is accelerated
by OS.34,35 Therefore, the experimental models used in our
studies, consisting of HG-, OS-, or AGE-treated retinal explants,
are modeling the three main factors characterizing the condition
of the retina in early DR
FIGURE 4. Caspase-3 and VEGF mRNA expressions, evaluated with qPCR, in HG- (A, B), OS- (C, D), and AGE- (E, F) treated explants incubated with
the high stressor dose and for the long incubation time in the presence or absence of OCT or PACAP. *P < 0.05, **P < 0.01 relative to untreated; §§P
< 0.01 relative to treatment with stressor alone.
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FIGURE 5. Vascular endothelial growth factor levels, evaluated with ELISA, in AGE-treated explants and in their incubation media at the short and
the long incubation times in the presence of the low or the high dose of AGE. Vascular endothelial growth factor levels were measured in the retinal
tissue (A) or in the incubation medium (B). The ratio VEGF in the tissue/VEGF in the medium (C) indicates whether VEGF is mainly released or
retained in the cells; the sum VEGF in the tissueþVEGF in the medium (D) indicates possible variations in total VEGF. *P < 0.05, **P < 0.01 relative
to untreated.
FIGURE 6. Vascular endothelial growth factor release, evaluated with ELISA, in HG- (A), OS- (B), and AGE- (C) treated explants incubated with the
high stressor dose and for the short incubation time in the presence or absence of OCT or PACAP. *P < 0.05, ***P < 0.001 relative to untreated; §P <
0.05, §§§P < 0.001 relative to treatment with stressor alone.
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In in vivo models of DR and in the retinas of patients with
diabetes, cell death has been reported mainly in ganglion cells
and in amacrine cells, while the data relative to photoreceptor
death or damage in diabetic retinas are not conclusive, as
recently reviewed.36 Similarly, apoptotic cells in our retinal
explants, visualized with caspase-3 immunoreactivity, were
primarily localized to INL and GCL, thus reinforcing the
similarities of these ex vivo models with the retina in early DR
VEGF as a Survival Factor in Early DR
Our observations show that VEGF expression and release are
concomitant and proportional to retinal damage induced by
HG, OS, or AGE. Possible interpretations of this finding are: (1)
VEGF increase and retinal damage are two independent
phenomena, (2) retinal damage induces VEGF increase, and
(3) VEGF increase provokes retinal damage. Our data strongly
suggest that inhibiting cell death also inhibits VEGF increase;
however, inhibiting VEGF does not result in reduced retinal
damage but rather provokes a significant increase of cell death.
Therefore, it appears that VEGF increase and retinal damage
are not independent phenomena. In addition, these observa-
tions suggest that VEGF levels in the early diabetic retina may
directly depend on the level of retinal damage.
In summary, our data support the hypothesis that VEGF
represents a sort of an emergency survival factor whose
production is commensurate with the extent of retinal cell
suffering in early DR. Consistent with this view, we have
observed increased VEGF release by retinal explants in acute
ischemia, which was reduced when the retinas were treated
with neuroprotective peptides.7,8 In addition, glutamate
excitotoxicity, one of the major causes of retinal neuronal
death in DR, has been reported to upregulate VEGF production
in diabetic retinas,37 while inhibition of glutamate receptors
results in a decrease of vitreoretinal VEGF in diabetic rats.38
Similarly, the antioxidant resveratrol has been found to block
the early increase of retinal VEGF caused by streptozotocin-
induced diabetes.39 In general, observations of brain reaction
to damage suggest that, in addition to death pathways, also
protective mechanisms are activated in the injured brain and
imply that the central nervous system possesses intrinsic
cytoprotective mechanisms that are likely to be mediated by
chemical signals derived from the injured brain itself.40
Vascular endothelial growth factor may be one of such signals
released by the retina in the early phases of DR in response to
the damage caused by increased glucose levels. Interestingly, it
has been reported that the optic nerve and retinal ganglion
cells in a rat model of experimental glaucoma are protected
from degeneration by short-term hyperglycemia.41 Recent
findings indicate that, in DR, VEGF may exert neuroprotective
effects mediated by Mu¨ller cells responding to VEGF with their
VEGFR2 receptors.42
In keeping with the proposed role of VEGF as a survival
factor expressed and released in the retina in response to acute
diabetic stress, our results provide direct evidence of
neuroprotective effects of VEGF in our ex vivo models. Several
studies have convincingly demonstrated the neuroprotective
potential of VEGF in a variety of retinal pathologic condi-
tions,15–18 although VEGF blockade does not seem to affect the
healthy retina.43,44 Our data strongly suggest that VEGF is the
main protective factor released by the retina to protect itself
from the damage caused by DR. One may wonder why, in the
course of evolution, VEGF has been preferred to other
neuroprotective factors (for instance neurotrophins) to protect
the retina in DR, in spite of its detrimental proangiogenic
effects resulting, in the long run, in the proliferative phase of
DR. It should be considered that under diabetic conditions, not
only retinal neurons but also vascular endothelial cells and
FIGURE 7. Immunofluorescence for active caspase-3 in untreated retinal explants (A), or in explants incubated with a VEGF trap (VT, [B]), with the
low dose of the HG model (C), with low dose-HG and VT (D), or with low dose-HG and VT preincubated with recombinant VEGF (E) for the HG
long incubation period. (F) Quantitative analysis of mean immunofluorescence levels. (G) Caspase-3 mRNA expression evaluated with qPCR. Retinal
layers are visualized with DAPI counterstain. Scale bar: 50 lm. *P < 0.05, **P < 0.01 relative to untreated; §P < 0.05, §§P < 0.01 relative to treatment
with stressor alone.
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pericytes undergo progressive degeneration.45 Vascular endo-
thelial growth factor is known to be an important growth
factor for endothelial cells46 and its upregulation in early DR
may have the dual objective of protecting both retinal neurons
and endothelial cells. This view is supported by recent findings
documenting both neurodegeneration and vascular damage
induced by repeated intravitreal injections of VEGF inhibitors
in the eyes of Ins2(Akita) diabetic mice.18
Neuroprotective Effects of OCT and PACAP
In our experiments, neuroprotection was provided by OCT or
PACAP. In principle, we could not exclude potential side
effects of OCT or PACAP treatments, which may affect the
structure of retinal explants or induce apoptosis in a caspase-
independent manner.47 The retinal structure, as seen in DAPI
counterstained sections, was apparently similar in untreated
explants and in explants treated with OCT or PACAP; therefore,
we can reasonably conclude that no side effects are induced by
OCT or PACAP treatments.
We assumed that neither OCT nor PACAP could significantly
influence VEGF levels per se. In effect, if OCT has well-
documented neuroprotective effects in the retina,7,8,22 it has
also been demonstrated to efficiently inhibit hypoxia-induced
VEGF expression both in the in vivo model of oxygen induced
retinopathy (OIR)48 and in ex vivo retinal explants cultured in
hypoxia, where the intracellular mechanisms affected by OCT
to inhibit VEGF expression have been identified.31 Although
we cannot exclude, in principle, that such mechanisms are also
activated by OCT in our ex vivo models of DR, it should be
noted that our explants were cultured in normoxia and were
never subjected to hypoxic conditions. Therefore, a direct
action of OCT on hypoxia-induced VEGF expression, such as
that described in the literature, is unlikely in our experimental
settings. These questions will be better addressed with further
studies to define the intracellular signaling mechanisms
activated by OCT in our ex vivo models of DR.
Pituitary adenylate cyclase activating peptide has been
reported to exert neuroprotective functions in a variety of
retinal injuries21 and in the retina of streptozotocin-treated
rats.23,49,50 Regarding possible direct effects on VEGF, most
experimental evidence reports an inducing, and not inhibito-
ry, effect of PACAP on VEGF. Indeed, PACAP treatment results
in increased VEGF in rat retinal hypoperfusion,51 in lung
cancer cells,52 and in pituitary folliculostellate cells.53 In
addition, PACAP does not appear to influence the hypoxia-
induced neoangiogenic response characterizing the OIR
model (G. Casini, R. Amato, and M. Dal Monte, unpublished
observation, 2015). In a recent paper, intraocular PACAP
administrations have been reported to decrease the expres-
sion of hypoxia-inducible factor 1a, a positive VEGF regulator,
in the retina of streptozotocin-treated rats after 3 weeks from
diabetes induction, although data on actual VEGF expression
were not reported.54 In summary, we can reasonably assume
that the actions of OCT and of PACAP in our studies were
prevalently neuroprotective, with only little or no direct
effects on VEGF expression. On the other hand, it should be
also considered that if OCT and/or PACAP were direct
inhibitors of VEGF in our models, their effects should have
been similar to those of a VEGF trap, that is induction rather
than limitation of cell death.
CONCLUSION
The present study not only confirms and expands the notion
that neurodegeneration is likely to play an essential role in
the pathogenesis of DR, but also indicates that VEGF is a
critical survival factor for retinal cells stressed by factors (HG,
OS, and AGE) characterizing the early phases of DR.
Therefore, if, on the one hand, it is reasonable to hypothesize
that therapeutic strategies based on neuroprotection will be
effective in preventing or arresting DR development, on the
other it appears that an anti-VEGF approach would be
detrimental if performed in early DR. Based on our and
others’ data, protecting retinal neurons reduces possible loss
of function and at the same time limits VEGF expression and
release, thus reducing the possibility of progression to the
proliferative phase of DR. Naturally occurring substances
such as peptides with neuroprotective action represent a
stimulating perspective for treatment of early DR. In this
respect, topical administration of somatostatin have been
found to prevent retinal neurodegeneration in streptozoto-
cin-induced diabetic rats.55 With this basis, a multicentric,
phase II-III, randomized controlled clinical trial (EURO-
CONDOR) to assess the efficacy of topically administered
somatostatin to counteract retinal neurodegeneration in DR
is ongoing.
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